ApoCell will present the study abstracts of its circulating tumor cells (CTC) recovery technology at the Molecular Targets and Cancer Therapeutics Conference, which will be held in Dublin, Ireland from 6-9 November 2012.
Using a low-level electrical field of varying frequencies in a special fluid chamber, the new technology extracts CTCs to identify disease progression in patients with prostate cancer.
The two studies are designed specifically to look at receptor expressions of harvested CTCs using the available CellSearch technology.
The studies conclude that there is a need for real time molecular profiling of the patient’s cancer to develop a treatment strategy, according to the company.
In addition to prostate cancer detection, ApoStream can capture larger numbers of CTCs in a live and viable state for additional research and has proven effective in capturing CTCs from liver cancer patients, which has not previously been possible.
The company said using captured CTCs, researchers and doctors can also monitor a patient’s response to drug therapies.